XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.3
Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Statement of Comprehensive Income [Abstract]        
Collaboration and license revenue $ 0 $ 6,551 $ 39,111 $ 17,738
Grant revenue 387 0 561 0
Total revenue 387 6,551 39,672 17,738
Operating expenses:        
Research and development 11,400 13,002 33,799 49,408
General and administrative 6,562 6,614 23,039 18,414
Total operating expenses 17,962 19,616 56,838 67,822
Operating loss (17,575) (13,065) (17,166) (50,084)
Investment income 2,573 1,299 4,932 4,024
Foreign currency transaction, net 0 (3) 0 39
Interest expense 0 (1,273) 0 (2,833)
Change in fair value of warrant liabilities 5,669 3,787 2,803 6,049
Change in fair value of contingent value right liability (15,100) 0 (51,900) 0
Change in fair value of forward contract liabilities 0 0 (6,890) 0
Other income, net 250 253 1,050 753
Net loss (24,183) (9,002) (67,171) (42,052)
Other comprehensive income (loss):        
Foreign currency translation adjustment (15) (20) (6) (69)
Unrealized gain on marketable securities 0 0 0 11
Total comprehensive income (loss) (24,198) (9,022) (67,177) (42,110)
Net loss $ (24,183) $ (9,002) $ (67,171) $ (42,052)
Net loss per share:        
Basic (in dollars per share) $ (1.13) $ (1.74) $ (4.61) $ (8.20)
Diluted (in dollars per share) $ (1.13) $ (1.74) $ (4.61) $ (8.20)
Weighted-average common shares outstanding:        
Basic (in shares) 21,471,408 5,160,150 14,561,613 5,129,030
Diluted (in shares) 21,471,408 5,160,150 14,561,613 5,129,030